SPRING BK PHARMACEUTICALS IN's ticker is SBPH and the CUSIP is 849431101. A total of 35 filers reported holding SPRING BK PHARMACEUTICALS IN in Q3 2017. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2020 | $486,000 | -8.8% | 363,114 | 0.0% | 0.02% | -17.9% |
| Q2 2020 | $533,000 | +57.7% | 363,114 | 0.0% | 0.03% | +27.3% |
| Q1 2020 | $338,000 | -49.7% | 363,114 | -14.6% | 0.02% | -31.2% |
| Q4 2019 | $672,000 | -55.3% | 425,089 | -2.9% | 0.03% | -55.6% |
| Q3 2019 | $1,505,000 | -1.1% | 437,589 | +6.2% | 0.07% | -5.3% |
| Q2 2019 | $1,522,000 | -64.8% | 412,049 | 0.0% | 0.08% | -62.7% |
| Q1 2019 | $4,323,000 | +1.0% | 412,049 | 0.0% | 0.20% | -6.8% |
| Q4 2018 | $4,282,000 | -13.7% | 412,049 | 0.0% | 0.22% | -25.5% |
| Q3 2018 | $4,964,000 | +1.7% | 412,049 | 0.0% | 0.29% | -5.8% |
| Q2 2018 | $4,883,000 | -22.9% | 412,049 | 0.0% | 0.31% | -27.9% |
| Q1 2018 | $6,336,000 | +14.4% | 412,049 | 0.0% | 0.43% | +2.1% |
| Q4 2017 | $5,539,000 | +13.0% | 412,049 | +13.8% | 0.42% | +19.1% |
| Q2 2017 | $4,902,000 | +77.4% | 362,049 | +16.6% | 0.36% | +53.4% |
| Q1 2017 | $2,763,000 | – | 310,490 | – | 0.23% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BVF INC/IL | 785,950 | $9,314,000 | 0.91% |
| Morse Asset Management, Inc | 177,500 | $2,103,000 | 0.58% |
| PARSONS CAPITAL MANAGEMENT INC/RI | 281,213 | $3,332,000 | 0.38% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 73,000 | $860,000 | 0.33% |
| TIEDEMANN ADVISORS, LLC | 412,049 | $4,883,000 | 0.31% |
| Private Capital Advisors, Inc. | 52,335 | $620,000 | 0.19% |
| SECTORAL ASSET MANAGEMENT INC | 131,656 | $1,560,000 | 0.17% |
| Lee Financial Co | 18,750 | $222,000 | 0.05% |
| Baker Brothers Advisors | 373,144 | $4,422,000 | 0.03% |
| Alyeska Investment Group, L.P. | 200,000 | $2,370,000 | 0.02% |